Title |
Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate |
Author |
Jin Soo Shin1, Keun Bon Ku1, Yejin Jang1, Yi-Seul Yoon1, Daeho Shin1,2, Oh Seung Kwon1,2, Yun Young Go1,2, Seong Soon Kim2,3, Myoung Ae Bae2,3, and Meehyein Kim1,2* |
Address |
1Center for Virus Research and Testing, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea, 2Department of Medicinal Chemistry and Pharmacology, Korea University of Science and Technology, Daejeon 34113, Republic of Korea, 3Drug Discovery Platform Technology Research Group, Korea Research Institute of Chemical Technology, Daejeon 34113, Republic of Korea |
Bibliography |
Journal of Microbiology, 55(12),979-983, 2017,
|
DOI |
10.1007/s12275-017-7371-x
|
Key Words |
oseltamivir free base, influenza virus, antiviral,
histopathology, pharmacokinetics |
Abstract |
Influenza viruses are major human respiratory pathogens that
cause high morbidity and mortality worldwide. Currently,
prophylactic vaccines and therapeutic antiviral agents are used
to prevent and control influenza virus infection. Oseltamivir
free base (OSV-FB), a modified generic antiviral drug of
Tamiflu (oseltamivir phosphate, OSV-P), was launched in
the Republic of Korea last year. Here, we examine the bioequivalence
of these two compounds by assessing their antiviral
efficacy in infected cells and in a mouse model. It was
observed that both antivirals showed comparable efficacy
against 11 different influenza A and B viruses in vitro. Moreover,
in mice infected with influenza A virus (mouse-adapted
A/Puerto Rico/8/34), they showed a dose-dependent therapeutic
activity and alleviated infection-mediated reductions
in body weight, leading to significantly better survival. There
was histopathological disappearance of virus-induced inflammatory
cell infiltration of the lung after oral treatment with
either antiviral agent (at 10 mg/kg). Pharmacokinetic analysis
also exhibited similar plasma concentrations of the active
drug, oseltamivir carboxylate, metabolised from both OSVB
and OSV-P. This is the first report showing bioequivalence
of OSV-FB to its phosphate salt form in the mouse system.
The free base drug has some beneficial points including simple
drug formulation process and reduced risk of undesirable
cation-phosphate precipitation within solution. The long term
stability of OSV-FB requires further monitoring when it is
provided as a national stock in readiness for an influenza
pandemic. |